NCT06418464Not yet recruitingNot Applicable
Efficacy and Safety of an Artificial-pancreas-like Learning-based Control in Type 1 Diabetes on Multiple Daily Injection Therapy: Protocol of a Multi-center, Non-inferiority, Randomized Controlled Trial (ELITE Study)
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 120
- Primary Endpoint
- Time in Range (TIR)
Study Overview
Brief Summary
This study is designed as a blinded, multi-center, non-inferiority randomized controlled clinical trial. It aims to enroll hospitalized T1D diabetes patients, ensuring an equal distribution with a 1:1 ratio between the intervention and control groups. The trial is set to take place across three locations in China: Peking University People's Hospital, Hebei Provincial People's Hospital, and Xingtai People's Hospital. Before participating, all subjects are required to provide their consent by signing a written informed consent form. Within the framework of the trial, the intervention group will receive insulin dosage recommendations from AP-A, subject to approval by a physician, whereas the control group will be treated with insulin dosages according to the current clinical guidelines established by their physicians.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Voluntary signing of an informed consent form.
- •Age between 18 and 70 years, with a T1D diagnosis of at least one year.
- •A confirmed diagnosis of T1D diabetes by at least two endocrinologists and fulfillment of at least one of the following conditions: a) Fasting C-peptide level less than 0.3 ng/mL. b) Fasting C-peptide level between 0.3 ng/mL and 0.6 ng/mL with at least one positive diabetic autoantibody.
- •Receiving intensified treatment regimen with multiple daily subcutaneous insulin injections upon screening and during the whole study period.
Exclusion Criteria
- •Conditions such as diabetic ketoacidosis, diabetic ketosis, hyperglycemic hyperosmolar state, or other acute complications related to diabetes.
- •The presence of concurrent fever, severe infections, acute abdominal conditions, uncontrolled thyroid dysfunction, or the acute phase of any organ system disease.
- •A history within the last 3 months of serious cardiovascular issues including decompensated heart failure (NYHA Class III or IV), myocardial infarction, coronary artery bypass grafting, or coronary stent implantation, as well as uncontrolled severe arrhythmias or ischemic or hemorrhagic stroke.
- •Laboratory test abnormalities that exceed certain thresholds, such as alanine transaminase or aspartate transaminase levels greater than three times the upper limit of normal, total bilirubin levels more than twice the upper limit of normal, hemoglobin levels below 100 g/L, albumin levels below 30 g/L, or an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m².
- •Individuals who are required to fast or are unable to eat normally due to special circumstances.
- •Pregnant or breastfeeding women.
- •Individuals suffering from psychiatric illnesses or other cognitive impairments that may affect their ability to participate in the study.
- •Participants who are unable to wear a CGM due to severe allergies, skin diseases, or conditions at the sensor site such as lesions, scarring, redness, infection, or edema, which could interfere with the sensor's adhesion or the accuracy of glucose measurements in the interstitial fluid.
- •The systemic use of corticosteroids within the last month, with the exception of inhaled or topical steroids.
- •Any other condition or reason that the researcher deems to make the participant unsuitable for inclusion in the study.
Outcomes
Primary Outcomes
Time in Range (TIR)
Time Frame: At the end of the treatment period
The proportion of time that the glucose levels, as recorded by CGM during the treatment period, are within the range of 3.9mmol/L to 10.0mmol/L. This metric can be directly obtained by the algorithm system through closed-loop reading of CGM data.
Secondary Outcomes
- Time Below Range (TBR)(At the end of the treatment period)
- Other Secondary Outcomes4(At the end of the treatment period)
- Other Secondary Outcomes7(At the end of the treatment period)
- Other Secondary Outcomes10(At the end of the treatment period)
- Other Secondary Outcomes6(At the end of the treatment period)
- Other Secondary Outcomes8(At the end of the treatment period)
- Other Secondary Outcomes1(At the end of the treatment period)
- Other Secondary Outcomes2(At the end of the treatment period)
- Other Secondary Outcomes3(At the end of the treatment period)
- Other Secondary Outcomes11(At the end of the treatment period)
- Other Secondary Outcomes5(At the end of the treatment period)
- Other Secondary Outcomes9(At the end of the treatment period)
Investigators
Wei Liu
Associate Professor
Peking University People's Hospital
Similar Trials
Active, not recruiting
Not Applicable
Closed Loop From Onset in Type 1 DiabetesDiabetes MellitusType 1 DiabetesNCT02871089University of Cambridge96
Completed
Not Applicable
Is the Artificial Pancreas, Without Carbohydrate Counting, Efficient and Safe in an Outpatient SettingAutoimmune DiabetesType 1 DiabetesNCT04793165Hospital Italiano de Buenos Aires5
Completed
Early Phase 1
Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal InsulinType 1 Diabetes MellitusNCT01929798Sansum Diabetes Research Institute36
Completed
Not Applicable
Assessment of Hybrid Use of an Artificial Pancreas in a Home setting for Two Months in Patients with Type 1 Diabetes - DiAs Hybrid Home TrialdiabetesNL-OMON41525Academisch Medisch Centrum12
Recruiting
Not Applicable
Efficacy and Safety of Android Artificial Pancreas System in Adult Patients With Type 1 Diabetes Mellitus in ChinaGlucose Metabolism DisordersMetabolic DiseaseDiabetes MellitusEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesDiabetes Mellitus, Type 1NCT05726461Third Affiliated Hospital, Sun Yat-Sen University25